Logo image of RGLS

REGULUS THERAPEUTICS INC (RGLS) Stock Overview

NASDAQ:RGLS - US75915K3095 - Common Stock

8.16 USD
+0.02 (+0.25%)
Last: 6/24/2025, 8:00:02 PM
8.02 USD
-0.14 (-1.72%)
After Hours: 6/24/2025, 8:00:02 PM

RGLS Key Statistics, Chart & Performance

Key Statistics
52 Week High8.35
52 Week Low0.83
Market Cap564.92M
Shares69.23M
Float67.31M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.73
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO10-04 2012-10-04
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


RGLS short term performance overview.The bars show the price performance of RGLS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300 400

RGLS long term performance overview.The bars show the price performance of RGLS in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of RGLS is 8.16 USD. In the past month the price increased by 3.42%. In the past year, price increased by 357.14%.

REGULUS THERAPEUTICS INC / RGLS Daily stock chart

RGLS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.68 368.08B
AMGN AMGEN INC 13.28 155.90B
GILD GILEAD SCIENCES INC 14.83 142.38B
VRTX VERTEX PHARMACEUTICALS INC 22.86 99.27B
REGN REGENERON PHARMACEUTICALS 12.88 62.29B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.14B
ARGX ARGENX SE - ADR 76.39 43.34B
ONC BEONE MEDICINES LTD-ADR 6.24 36.72B
INSM INSMED INC N/A 27.94B
BNTX BIONTECH SE-ADR N/A 25.19B
NTRA NATERA INC N/A 22.74B
BIIB BIOGEN INC 8.54 20.04B

About RGLS

Company Profile

RGLS logo image Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The company went IPO on 2012-10-04. The firm is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The firm is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Company Info

REGULUS THERAPEUTICS INC

4224 Campus Point Court, Suite 210

San Diego CALIFORNIA 92121 US

CEO: Joseph P. Hagan

Employees: 34

RGLS Company Website

RGLS Investor Relations

Phone: 18582026300

REGULUS THERAPEUTICS INC / RGLS FAQ

What is the stock price of REGULUS THERAPEUTICS INC today?

The current stock price of RGLS is 8.16 USD. The price increased by 0.25% in the last trading session.


What is the ticker symbol for REGULUS THERAPEUTICS INC stock?

The exchange symbol of REGULUS THERAPEUTICS INC is RGLS and it is listed on the Nasdaq exchange.


On which exchange is RGLS stock listed?

RGLS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for REGULUS THERAPEUTICS INC stock?

12 analysts have analysed RGLS and the average price target is 8.67 USD. This implies a price increase of 6.25% is expected in the next year compared to the current price of 8.16. Check the REGULUS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REGULUS THERAPEUTICS INC worth?

REGULUS THERAPEUTICS INC (RGLS) has a market capitalization of 564.92M USD. This makes RGLS a Small Cap stock.


How many employees does REGULUS THERAPEUTICS INC have?

REGULUS THERAPEUTICS INC (RGLS) currently has 34 employees.


What are the support and resistance levels for REGULUS THERAPEUTICS INC (RGLS) stock?

REGULUS THERAPEUTICS INC (RGLS) has a support level at 7.87 and a resistance level at 8.23. Check the full technical report for a detailed analysis of RGLS support and resistance levels.


Should I buy REGULUS THERAPEUTICS INC (RGLS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REGULUS THERAPEUTICS INC (RGLS) stock pay dividends?

RGLS does not pay a dividend.


When does REGULUS THERAPEUTICS INC (RGLS) report earnings?

REGULUS THERAPEUTICS INC (RGLS) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of REGULUS THERAPEUTICS INC (RGLS)?

REGULUS THERAPEUTICS INC (RGLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).


RGLS Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to RGLS. When comparing the yearly performance of all stocks, RGLS is one of the better performing stocks in the market, outperforming 99.47% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

RGLS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RGLS. RGLS has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RGLS Financial Highlights

Over the last trailing twelve months RGLS reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -63.51%
ROE -68.85%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%48.28%
Sales Q2Q%N/A
EPS 1Y (TTM)50%
Revenue 1Y (TTM)N/A

RGLS Forecast & Estimates

12 analysts have analysed RGLS and the average price target is 8.67 USD. This implies a price increase of 6.25% is expected in the next year compared to the current price of 8.16.


Analysts
Analysts73.33
Price Target8.67 (6.25%)
EPS Next Y-5.52%
Revenue Next YearN/A

RGLS Ownership

Ownership
Inst Owners82.87%
Ins Owners2.8%
Short Float %N/A
Short RatioN/A